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Abstract
Background/Methods: We have examined the hypothesis that cyst formation is key in the pathogenesis of
cardiovascular disease in a Lewis polycystic kidney (LPK) model of autosomal-recessive polycystic kidney
disease (ARPKD), by determining the relationship between cyst development and indices of renal function
and cardiovascular disease. Results: In the LPK (n = 35), cysts appear at week 3 (1.1 ± 0.1 mm) increasing to
week 24 (2.8 ± 2 mm). Immunostaining for nephron-specific segments indicate cysts develop predominantly
from the collecting duct. Cyst formation preceded hypertension (160 ± 22 vs. Lewis control 105 ± 20 mm Hg
systolic blood pressure (BP), n = 12) at week 6, elevated creatinine (109 ± 63 vs. 59 ± 6 μmol/l, n = 16) and
cardiac mass (0.7 vs. 0.4% bodyweight, n = 15) at week 12, and left ventricular hypertrophy (2,898 ± 207 vs.
1,808 ± 192 μm, n = 14) at week 24 (all p ≤ 0.05). Plasma-renin activity and angiotensin II were reduced in
10- to 12-week LPK (2.2 ± 2.9 vs. Lewis 11.9 ± 4.9 ng/ml/h, and 25.0 ± 19.1 vs. 94.9 ± 64.4 pg/ml,
respectively, n = 26, p ≤ 0.05). Ganglionic blockade (hexamethonium 3.3 mg/kg) significantly reduced mean
BP in the LPK (52 vs. Lewis 4%, n = 9, p ≤ 0.05). Conclusion: Cyst formation is a key event in the genesis of
hypertension while the sympathetic nervous system is important in the maintenance of hypertension in this
model of ARPKD.
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(0.7 vs. 0.4% bodyweight, n = 15) at week 12, and left ven-
tricular hypertrophy (2,898  8 207 vs. 1,808  8 192   m, n = 
14) at week 24 (all p  ̂  0.05). Plasma-renin activity and an-
giotensin II were reduced in 10- to 12-week LPK (2.2  8 2.9 vs. 
Lewis 11.9  8 4.9 ng/ml/h, and 25.0  8 19.1 vs. 94.9  8 64.4 
pg/ml, respectively, n = 26, p  ̂  0.05). Ganglionic blockade 
(hexamethonium 3.3 mg/kg) significantly reduced mean BP 
in the LPK (52 vs. Lewis 4%, n = 9, p  ̂  0.05).  Conclusion: Cyst 
formation is a key event in the genesis of hypertension while 
the sympathetic nervous system is important in the mainte-
nance of hypertension in this model of ARPKD. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Hypertension is a common and early clinical feature 
of both autosomal-dominant and -recessive variants of 
polycystic kidney disease (PKD)  [1, 2] and has a major 
role in the development of left ventricular hypertrophy 
(LVH) as well as the progression to end-stage renal failure 
 Key Words 
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 Abstract 
 Background/Methods: We have examined the hypothesis 
that cyst formation is key in the pathogenesis of cardiovas-
cular disease in a Lewis polycystic kidney (LPK) model of au-
tosomal-recessive polycystic kidney disease (ARPKD), by de-
termining the relationship between cyst development and 
indices of renal function and cardiovascular disease.  Results: 
In the LPK (n = 35), cysts appear at week 3 (1.1  8 0.1 mm) in-
creasing to week 24 (2.8  8 2 mm). Immunostaining for neph-
ron-specific segments indicate cysts develop predominant-
ly from the collecting duct. Cyst formation preceded 
hypertension (160  8 22 vs. Lewis control 105  8 20 mm Hg 
systolic blood pressure (BP), n = 12) at week 6, elevated cre-
atinine (109  8 63 vs. 59  8 6   mol/l, n = 16) and cardiac mass 
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 [3, 4] . An understanding of the pathogenesis and progres-
sion of hypertension is therefore critical to identifying 
key interventions and limiting morbidity in PKD. 
 The mechanisms of hypertension in PKD are not well 
defined and it has been hypothesised that one of the ini-
tial precipitants is the development of gross abnormali-
ties in renal structure due to cyst formation causing local 
tissue ischaemia and the activation of a variety of media-
tors including the renin-angiotensin-aldosterone system 
(RAAS), vasoactive peptides and sympathetic nervous 
system (SNS)  [5, 6] . This would suggest that hypertension 
occurs simultaneously with cyst formation, and precedes 
development of LVH. Indeed, this is consistent with clin-
ical experience and cross-sectional studies of humans 
with PKD  [5, 7] . The prospective evaluation of this hy-
pothesis in humans is difficult and requires examination 
in animal models. In that regard, a number of mouse and 
rat models of PKD are described. In the rat, all known 
models are the result of spontaneous genetic mutations, 
while in mice many have been engineered through chem-
ical induction or insertional mutagenesis including tar-
geted mutagenesis of human PKD orthologs  [8, for re-
view]. However, to date these models of PKD including 
the heterozygous Han:SPRD PKD and autosomal-reces-
sive PKD (ARPKD)  wpk animals show either no or only 
mild-to-moderate elevations in blood pressure  [9–11] and 
no evidence of progressive cardiovascular disease. Fur-
thermore, genetically engineered mouse models may 
have specific defects in the cardiovascular system, which 
may make interpretation complicated  [12] . 
 We have examined the overriding hypothesis that cys-
togenesis is a key event in the pathogenesis of cardiovascu-
lar disease in PKD by undertaking a temporal analysis of 
renal morphology, indices of renal function, blood pres-
sure and cardiac hypertrophy in a new Lewis rat model of 
PKD (LPK). In order to gain an appreciation of the mech-
anisms driving hypertension, we have also examined the 
respective contributions of RAAS and SNS. Preliminary 
data regarding the LPK model  [13] indicates the key trait 
of marked hypertension from an early age, with inheri-
tance features suggestive of ARPKD. Classically, the cystic 
lesions in ARPKD arise predominantly from the collecting 
duct  [8] whereas in autosomal-dominant PKD (ADPKD), 
recent data suggest cysts arise predominantly from the dis-
tal nephron  [14, 15] . Therefore, in order to determine the 
site of origin of cysts in the LPK model, we have performed 
immunohistochemistry to: (1) determine the nephron-
segment origin of the cysts, and (2) assess the degree of 
tubulointerstitial damage, a common histological accom-
paniment of PKD and predictor of progression. 
 Materials and Methods 
 Animals 
 All experiments were carried out with the approval of the An-
imal Ethics committees of the respective institutions. Lewis rats 
with PKD arising as a spontaneous mutation were identified at 
the Animal Resources Centre, Perth Australia (2002) in a LEW/
SsNArc (Lewis) inbred strain originally received from the De-
partment of Health and Human Services, National Institute of 
Health, USA (1990). The Lewis animals with PKD (LPK) were 
inbred by brother/sister matings of affected littermates and main-
tained as an inbred colony. Standard inbred Lewis rats (LEW/
CrlBR) bred at the Animal Resources Centre were used as a con-
trol strain. The LPK females produced one litter of 8–12 pups at 
12–15 weeks of age and did not reproduce again. Animals did not 
survive beyond 26 weeks of age. 
 In order to characterise the mode of inheritance, mating ex-
periments were performed. LPK  ! LPK crossings yielded off-
spring which all exhibited renal cysts (50 pairs, 345 [100%] poly-
cystic progeny). Brown Norway (BN)  ! LPK crossings (F1) 
yielded offspring with no detectable cysts (3 pairs, 3 litters, 18 
progeny). For the F1  ! F1 crossings (F2; 16 pairs, 16 litters, 152 
offspring), 38 developed cystic kidneys (25%,   2  value = 0.00,
p  ! 0.05). This frequency of PKD in F2 animals supports an au-
tosomal recessive pattern of Mendelian inheritance for a single 
gene mutation. 
 Experimental Design and Assessment of Blood Pressure 
 Whole body and tissue-specific measurements were collected 
from LPK and Lewis rats at the time points of 3, 6, 12, 16 and 24 
weeks of age. At each time point, a minimum of 6 rats (3 female, 
3 male) of each strain was used (n = 36 LPK rats, 31 Lewis rats). 
Prior to CO 2  euthanasia, body weight and tail-cuff blood pressure 
measurements were made (average of 3 measurements after ac-
climatization; NIBP controller, ADI Instruments, Castle Hill, 
NSW, Australia) and voided urine samples collected. Urine was 
not collected from 3-week-old animals. Immediately following 
euthanasia, blood was collected by cardiac puncture and wet
kidney, heart, pancreas and liver weight recorded. Three other 
additional groups of animals were used. A group of mixed sex 1-
week-old LPK and Lewis rats (n = 6 each strain, total 12 rats) were 
euthanised and renal tissue collected and processed for morpho-
metric quantification. A group of mixed sex 10- to 12-week-old 
LPK and Lewis rats (n = 18 and 8, respectively, total 26 rats) were 
used for collection of blood for plasma-renin activity (PRA), an-
giotensin II (Ang II) and aldosterone analysis. After stunning and 
decapitation, blood was collected in chilled tubes containing Na 2 
 EDTA, the plasma collected and then stored at –80  °  C until fur-
ther hormonal analysis. Additional blood was collected for serum 
urea and creatinine levels. A final group of mixed sex 16-week-old 
LPK and Lewis rats (n = 4 Lewis, 5 LPK, total 9 animals) were used 
for ganglionic blockade. Animals were anaesthetised with ure-
thane (Sigma-Aldrich, Mo., USA; 1.2 g/kg i.p.) and a cannula was 
placed in the femoral artery. The cannula was connected via a 
bridge amplifier to a Powerlab (AD Instruments) data system. 
The ganglionic blocking agent hexamethonium bromide (Sigma) 
was administered subcutaneously (3.3 mg/kg) during continuous 
measurement of arterial pressure and heart rate. Preliminary 
studies indicated this dosage as one that produced consistent and 
tolerated effects in the LPK. Systolic pressure, diastolic pressure, 
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mean arterial pressure (MAP) and heart rate were continuously 
measured until reaching a steady level within 3–5 min of drug 
administration. 
 Clinical Biochemistry and Haematology 
 Full biochemical profiles were performed on animals at weeks 
6, 12 and 24. At 3 and 16 weeks, only serum urea and creatinine 
were determined. Serum creatinine, urea, protein, bilirubin, al-
kaline phosphatase (ALP), aspartate amino transferase (AST) and 
alanine amino transferase (ALT) were measured using a Rx Day-
tona analyser (Randox Laboratories, Antrum, UK). PRA and Ang 
II levels were determined by radioimmunoassay (ProSearch In-
ternational Australia, Malvern, Vic., Australia). Plasma aldoste-
rone concentrations were ascertained using a commercially avail-
able radioimmunoassay kit (Count a Coat, Diagnostic Products 
Corporation, California, USA, undertaken by ProSearch Interna-
tional Australia). Micro haematocrit tubes were used to deter-
mine packed cell volume (PCV). Urine specific gravity (USG) was 
measured using a refractometer and urine protein to creatinine 
ratio determined using a Cobas Mira analyser (Roche Diagnos-
tics, Schweiz, AG). 
 Tissue Histology 
 The heart, liver and pancreas were placed into 4% formalin 
prior to embedding in paraffin wax for histological analysis. Liv-
er, pancreas and a mid-ventricle section of the heart were stained 
with haematoxylin and eosin (HE) and examined by standard 
light microscopy. Coronal sections of the kidney were fixed in 
methyl Carnoy’s solution or 4% formalin and after paraffin em-
bedding, 4-  m-thick sections were stained with periodic acid-
Schiff (PAS) for cyst morphometric analysis and Gomori’s tri-
chrome for histological assessment of collagen deposition. 
 Immunohistochemistry of the Kidney 
 To assess the degree of tubulointerstitial damage, and origin 
of cyst formation, immunohistochemistry using the primary and 
secondary antibodies as indicated in  table 1 was performed. For 
tubulointerstitial damage, markers for interstitial inflammation 
(macrophage/monocytes, detected by ED-1 antigen), interstitial 
myofibroblast accumulation (  -smooth muscle actin, SMA), tu-
bular dedifferentiation (vimentin, an intermediate filament pro-
tein expressed in dedifferentiated but not normal epithelia) and 
tubular epithelial cell (TEC) proliferation (proliferating cell nu-
clear antigen, PCNA) were used. For determination of cyst origin, 
the primary antibodies against the following specific nephron 
segments were used: aquaporin-1 (AQP1) which is a marker for 
the proximal convoluted tubule and the thin descending limb of 
Henle’s loop  [16] ; Tamm-Horsfall glycoprotein (THG) which is 
expressed by the thick ascending limb and distal convoluted tu-
bule  [17] and aquaporin-2 (AQP2), whose expression is localised 
to the apical domains in the principal cells of the cortical and 
medullary collecting ducts  [18, 19] . 
 Table 1. Primary and secondary antibodies used for kidney immunohistochemistry 
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 Primary antibodies were incubated at 4  °  C overnight, followed 
by biotinylated species-specific secondary antibodies. All second-
ary antibodies were used at a dilution of 1:  400 and were from 
Zymed Laboratories (San Francisco, Calif., USA) except for the 
biotinylated goat anti-mouse immunoglobulins IgG (1: 400, Dako, 
Botany, NSW, Australia). Sections were incubated for 30 min with 
secondary antibodies. All primary and secondary antibodies 
were diluted using phosphate buffered saline (PBS; pH 7.4) with 
1% bovine serum albumin (BSA) and 1% Tween-20. Immunore-
activity was visualised with Vectastain Elite ABC  reagent (Vec-
tor Laboratories, Burlingame, Calif., USA) and the chromogen 
diaminobenzidine (DAB; Sigma-Aldrich). Methyl-green 2% was 
used for counterstaining followed by dehydration and application 
of cover slips using Histomount  (Invitrogen Corporation, Carls-
bad, Calif., USA). 
 Morphometric Quantification of the Kidney 
 Sections were viewed with a microscope and the images were 
digitalized using a video camera (BX51/ DP11; Olympus, Perth, 
WA, Australia) linked to image analysis software (Optimas Image 
Analysis, Version 5.2; Optimus Corp., Bothell, Wash., USA). A 
uniformly random cluster method was used to determine micro-
scopic fields for evaluation  [20] . 
 To assess cyst formation, cross-sectional diameter of individ-
ual cortical cysts was measured using line morphometry, with 
diameter defined as the length of a straight line joining two points 
on the cyst circumference. Subjectively, the greatest length pos-
sible between two points was taken and the largest cysts within 
mid-cortical fields assessed. Mean average diameter for each sec-
tion was determined. 
 Tubulointerstitial fibrosis was evaluated by quantitative image 
analysis for percentage area occupied by positive staining for
interstitial   -SMA in five mid-cortical fields. Magnification 
 ! 200. 
 Interstitial collagen deposition (Trichrome blue) was assessed 
semiquantitatively from 0 to 4: 0, absent; 1,  ! 25% of or deposition 
of interstitial collagen ( ! 25%); 2, 25–50% of or deposition of in-
terstitial collagen (25–50%); 3, 51–75% of or deposition of inter-
stitial collagen (50–75%), and 4, 76–100% of deposition of inter-
stitial collagen ( 1 75%). An average grade was established for each 
section to determine a mean grade for each time point. Five med-
ullary and five cortical fields from each animal were evaluated 
(magnification  ! 200, graticule 0.5 mm 2 ). 
 For tubulointerstitial inflammation, ED-1-positive and 
PCNA-positive interstitial cells were quantified in five midcorti-
cal fields measured at  ! 200. The number of positive cells in each 
field was counted and an average count was generated for each 
section. Mean cell counts for each time point were established 
(cells per mm 2 ). 
 For semi-quantitative analysis of tubular vimentin five corti-
cal fields from each animal were examined at  ! 200 magnifica-
tion and graded using a score as for collagen deposition. A tubule 
was defined as positive for vimentin if it contained  6 one immu-
noreactive tubular epithelial cell. 
 Morphometric Quantification of the Heart 
 A composite image of the heart was taken using a light micro-
scope (LEICA DMBRE, Wetzlar, Germany) and digital camera 
(NIKON DXM1200F, Nikon Corporation, Kawasaki, Kanagawa, 
Japan). The assessment of the thickness (  m) of the right ven-
tricular free wall, interventricular septum and left ventricular 
free wall were determined using Image ProPlus image analysis 
software (version 4.5.1.29, Media Cybernetics, LP, Md., USA). 
 Statistical Analyses 
 Results are presented as means  8 SD of combined male and 
female results unless otherwise stated. All analysis was conducted 
using the statistical package Statistical Package for the Social Sci-
ences (SPSS; Chicago, Ill., USA). Analysis was performed using a 
univariate general linear model against the fixed factors of age, 
strain and sex. Significance was set at p  ̂  0.05 and the adjusted 
R 2  (relative predictive powers of the model adjusted for degrees of 
freedom) provided. For tissue weights, data was converted to per-
centage body weight. Unless otherwise stated, data was not influ-
enced by blood pressure when entered as a covariate in the model. 
Level of statistical significance for the effect of strain is provided, 
and if present, age/strain and/or sex interactions. Results of the 
univariate analysis drove the Post Hoc analysis, performed using 
Tukey test (p  ̂  0.05). The correlation for aldosterone and creati-
nine was determined in the LPK using a Pearson correlation with 
a two-tailed test of significance, p  ̂  0.05. 
 Results 
 General Features 
 The gross phenotype of LPK rats was characterised by 
progressive nephromegaly ( fig. 1 a, b). Age, sex and strain 
all had a significant effect on bodyweight ( table 2 ). There 
was no macroscopic or microscopic evidence of cyst for-
mation in the liver or pancreas at any age ( fig. 1 c, d). The 
weight of the liver was significantly associated with age 
(proportionally smaller in younger animals) and was 
only different between the strains at 6 weeks (less in the 
LPK;  table 2 ). The pancreas showed no significant differ-
ences at any age. 
 LPK Rats Develop Laboratory Abnormalities 
Consistent with Progressive Kidney Failure 
 Serum urea was significantly elevated from 3 weeks in 
LPK rats and serum creatinine by 12 weeks, and both in-
creased with age ( table 3 ). Sex had a significant effect on 
the levels of urea and creatinine in the LPK animals, with 
males showing overall higher levels of both markers but 
there was no age/sex interaction ( fig. 2 ). Urinalysis dem-
onstrated isosthenuria in the LPK rats from week 12 on-
wards ( table 3 ) and the urine protein: creatinine ratio in-
creased significantly in the LPK animals from 16 weeks 
of age onwards ( table 3 ; p  ̂  0.05). At 12 weeks of age, 
protein (total and albumin) levels were significantly re-
duced in LPK animals when compared with the Lewis 
( table 4 ; p  ̂  0.05). Globulin levels were reduced in the 
LPK at 24 weeks of age ( table 4 ; p  ̂  0.05). Bilirubin and 
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the hepatic enzymes ALT and AST did not vary between 
the strains ( table 4 ). ALP levels showed an age effect, be-
ing higher in younger animals, which was more pro-
nounced in the Lewis (p  ̂  0.05). The PCV was less in the 
LPK group than age matched Lewis from week 12, and 
continued to decrease with increasing age ( table 4 , p  ̂  
0.05). The anaemia was characterised as normocytic and 
normochromic. 
 In the group of animals tested for PRA, Ang II and al-
dosterone, PRA levels were significantly less in the LPK 
when compared to Lewis at 10–12 weeks of age (2.2  8 2.9 
vs. 11.7  8 4.9 ng/ml/h, Adj R 2  = 0.599, p  ! 0.001, n = 26). 
Angiotensin II levels were also significantly less in the 
LPK (25.0  8 19.1 vs. Lewis 94.9  8 64.4 pg/ml, Adj R 2  = 
0.646, p  ! 0.001). Angiotensin II levels showed a sex/strain 
interaction, due to significantly higher levels of Ang II in 
the male Lewis animals (109.6  8 17.3 pg/ml, n = 4, p  ! 
a b
c d
 Fig. 1. Gross and microscopic tissue features. In-situ images of 
kidneys from a 12-week-old Lewis control ( a ) and 12-week-old 
LPK ( b ) rat. Figure illustrates the dramatic increase in size of the 
kidneys in LPK (arrow is pointing to left kidney in both panels) 
and their pale and nodular appearance. Figure also illustrates the 
normal gross appearance of the liver in the LPK ( * ).  c ,  d Light mi-
croscopy of histological sections of body tissues stained with HE. 
 c shows histologically normal liver tissue from a 24-week-old LPK 
animal, while  d shows histologically normal pancreas from a 12-
week-old animal LPK.  c ,  d Scale bar = 200   m. 
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0.001). Plasma aldosterone levels were not significantly 
different between the two groups (446.5  8 442.3 vs. Lew-
is 412.2  8 155.8 pg/ml), but there was a wide range in the 
LPK results. This prompted a correlation analysis that 
showed aldosterone levels in the LPK were positively cor-
related with creatinine (Pearson correlation co-efficient 
0.607, p = 0.008, n = 18). Creatinine was significantly dif-
ferent between LPK and Lewis in this cohort (73.7  8 38.3 
vs. 46.2  8 5.7   mol/l, respectively, p  ̂  0.05). 
 Kidney Cysts Arise from the Distal Nephron at Week 3 
 Kidney weight in LPK rats progressively increased ( ta-
ble 2 ), with the surface becoming more irregular due to 
cyst formation. Macroscopically, the reniform shape of 
 Table 2. Body weight and tissue features in age-matched Lewis and LPK rats 
Tissue 3 weeks 6 weeks 12 weeks 16 weeks 24 weeks Adjusted 
R2  value(6)LEW (6)LPK (6)LEW (6)LPK (7)LEW (8)LPK (6)LEW (6)LPK (6)LEW (8)LPK
Body, g 66811 4083 145821 160838 261875 210843 303858 248863 327886 237850 0.96***
Liver, % BW 4.780.4 4.580.3 5.480.3 4.080.2 4.280.5 3.580.4 4.380.5 3.580.7 3.480.7 3.280.8 0.91***
Pancreas, % BW 0.480.1 0.480.1 0.480.1 0.380.1 0.380.1 0.580.1 0.380.1 0.580.0 0.380.1 0.580.1 0.71
Kidneys, % BW 1.380.1 6.580.7 1.280.05 6.282.0 0.980.1 8.381.2 0.980.1 9.681.0 0.980. 2 9.283.5 0.90***
Data represent mean 8 SD of combined male and female data.  Minimum number of animals in each group indicated by superscript associated with 
age/strain column. Significance of strain effect: *** p ≤ 0.001.
 
 Table 3. Biochemical and urological parameters in age-matched Lewis and LPK rats 
Parameter 3 weeks 6 weeks 12 weeks 16 weeks 24 weeks Adjusted 
R2 value
(6)LEW (6)LPK (6)LEW (8)LPK (8)LEW (8)LPK (6)LEW (6)LPK (6)LEW (9)LPK
Urea, mmol/l 580.6 1382 580.3 1284 781 34823 780.3 44818 680.7 80821 0.83***
Creatinine, mol/l 5684 3084 4582 64813 5986 109863 4985 150870 5285 279870 0.87***
USG 1.04180.01 1.03980.0 1.01580.01 1.02380.01 1.02980.02 1.01280.0 1.01580.0 1.01180.0 1.03580.01 1.01380.0 0.50**
Urine Pr:Cr ratio – – 2.681.4 5.383.1 1.180.5 5.382.6 2.181.0 19.2818.5 1.681.2 31.8822.1 0.50***
Data represent mean 8 SD of combined male and female data. Urine specific gravity (USG; isosthenuria range 1.008–1.012), protein:creatinine (Pr:Cr, protein units g/l, cre-
atinine units mol/l; calculation (8,840) ! (urinary protein/urinary creatinine). Minimum number of animals in each group indicated by superscript associated with age/strain 














































6 12 16 24
Age (weeks)
*
Female LPK Male LPK
 Fig. 2. Graphical representation of elevation in serum urea ( a ) and 
creatinine ( b ) in male and female LPK animals. Serum urea levels 
increased with age for both sexes, and while there was no signifi-
cant difference between males and females at any time point, 
overall there were significantly higher levels in the male rats (ad-
justed R 2  = 0.754, sex effect p = 0.033). This effect was more pro-
nounced for serum creatinine ( b ; adjusted R 2  = 0.838, sex effect
p  ̂  0.001).  *  Significant difference between males and females at 
that age, p  ̂  0.05. Data are means  8 SD, n = 37. 
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the kidney remained intact in LPK animals. The cut sur-
face of the kidney had focal clusters of cysts that were 
present in the cortex and medulla in the distribution of 
medullary rays. At week 1, by light microscopy, focal ar-
eas of mild dilatation of proximal and distal tubules were 
present, but cysts were absent ( fig. 3 a). By week 3, epithe-
lial cell-lined cysts appeared throughout the cortex and 
medulla ( fig. 3 b) and the size increased progressively 
from 12 weeks ( fig. 3 c–f). Cysts were lined by cuboidal 
and flattened cells and resembled epithelia from distal 
nephron segments. Immunostaining for nephron-specif-
ic markers indicated that the majority of cysts stained 
strongly and consistently for aquaporin-2 ( fig. 4 a, b). In 
addition, some cells in the cysts stained positive for 
Tamm-Horsfall protein (THP;  fig. 4 c, d) and occasion-
ally medullary (but not cortical) cysts were positive for 
aquaporin-1 ( fig. 4 e, f), indicating that cysts arose pre-
dominantly from the collecting ducts and to a lesser ex-
tent from the distal convoluted tubule, thick ascending or 
thin descending limbs of the nephron. 
 Cyst Formation Is Associated with Tubule Cell 
Proliferation/Dedifferentiation and Progressive 
Tubulointerstitial Inflammation and Fibrosis 
 The number of PCNA-positive cortical tubule cells 
was significantly greater in the LPK rats ( fig. 5 ). Simi-
larly, the number of vimentin-positive cortical tubule 
cells was higher in affected LPK rats at all time points, 
significantly increasing to week 12 ( table 5 ). The number 
of interstitial ED-1-positive cells was significantly higher 
in the LPK animals at 6 and 12 weeks (p  ̂  0.05;  table 5 ). 
Diffuse collagen deposition within the renal parenchyma 
was significantly different to the Lewis from week 12 on-
wards, increasing further at 24 weeks (p  ̂  0.05,  table 5 ). 
Collagen deposition accompanied areas of tubular atro-
phy, glomerulosclerosis and/or areas dense in dedifferen-
tiated epithelial cells. Use of blood pressure as a covariate 
in the analysis indicated that collagen deposition in the 
cortex and medulla was significantly associated with 
blood pressure (p = 0.005, 0.018, respectively). Interstitial 
myofibroblast accumulation (  -SMA) was significantly 
higher in the LPK animals relative to age-matched con-
trols from week 6 (p  ̂  0.05;  table 5 ). 
 Hypertension Develops Early in LPK, Preceding 
Cardiac Hypertrophy, and Is Abrogated by Ganglionic 
Blockade 
 Tail cuff systolic blood pressures were elevated in LPK 
rats from week 6 onwards ( fig. 6 a). Proportional heart 
weight decreased in the Lewis and LPK between 3 and 6 
weeks, but then increased in the LPK, becoming signifi-
cantly greater than the Lewis from 12 weeks of age ( fig. 6 b). 
Proportional LPK heart weights were significantly associ-
ated with blood pressure when entered as a covariate in 
the model (p = 0.034, adjusted R 2  = 0.351). Hearts from 
the LPK rats showed no cysts ( fig. 6 c), but histological ex-
amination showed LVH, multifocal muscle degeneration, 
mild fibrosis, medial hypertrophy of cardiac vessels and 
increased perivascular mast cell infiltration. Measure-
ments of the left ventricular free wall confirmed LVH in 
the LPK at 24 weeks of age when compared to Lewis 
( fig. 6 d). The interventricular septum was also signifi-
cantly thicker in the LPK animals than aged matched 
Lewis at 24 weeks of age (2,096  8 178 vs. 1,370  8 188   m, 
 Table 4. Biochemical and haematological parameters in age-matched Lewis and LPK rats 
Parameter 6 weeks 12 weeks 24 weeks Adjusted 
R2 value(6)LEW (6)LPK (6)LEW (7)LPK (6)LEW (8)LPK
Total protein, g/l 6082 5583 6784 5784 6789 4789 0.60***
Albumin, g/l 3681 3480.7 4083 3282 3985 2885 0.67***
Globulin, calc g/l 2481 2282 2882 2582 2584 1984 0.53***
Total bilirubin, mol/l 280.0 484 381 684 2.480.7 580.8 –0.71
ALT, U/l 121840 1728168 58818 116897 1808142 49823 0.23
AST, U/l 2408110 4888478 135867 2738144 2428103 116853 0.21
ALP, U/l 530854 343880 229853 239841 200854 139839 0.84*
PCV 0.580.0 0.480.0 0.580.0 0.380.1 0.580.0 0.280.1 0.88***
Data represents mean 8 SD of combined male and female results. Globulin  = Calculated (calc) from total protein and albumin 
levels. Minimum number of animals in each group indicated by superscript associated with age/strain column. Significance of strain 
effect: * p ≤ 0.05; *** p ≤ 0.001.
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 Fig. 3. Cyst development in the LPK animals.  a–e : Light micros-
copy of PAS sections of LPK kidneys from animals aged 1 week 
( a ), 3 weeks ( b ), 6 weeks ( c ), 12 weeks ( d ) and 24 weeks ( e ). Figures 
illustrate absence of cysts in the first postnatal week ( a ) although 
focal areas of dilated proximal and distal convoluted tubules were 
present. At week 3 there was a rapid appearance of cysts through-
out the cortex and medulla ( b ) and these cysts continued to in-
crease in size as the animals aged ( b–e ).  a–e Scale bar = 1.0 mm. 
 f Cyst diameter (mm) as measured using line morphometry. After 
their appearance in week 3, the size of the cysts increased progres-
sively from 12 weeks onwards (p  ̂  0.05, adjusted R 2  = 0.916). 
Data are means  8 SD. n values are presented in  table 5 . 
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 Fig. 4. Immunohistochemical staining of kidney sections for 
aquaporin-2 ( a ,  b , medulla), Tamm-Horsfall protein ( c ,  d , me-
dulla) and aquaporin-1 ( e ,  f , cortex) in Lewis control ( a ,  c ,  e ) and 
LPK ( b ,  d ,  f ) animals at week 3. Epithelial cells lining cysts ( ** ) 
stained positive for aquaporin-2 (predominantly) and to a lesser 
extent Tamm-Horsfall protein (shown by arrows), but were rarely 
positive for aquaporin-1. Results therefore indicate that cysts arise 
predominantly from collecting ductules and the distal nephron. 
Original magnification  ! 200. 
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respectively, p  ̂  0.05, adjusted R 2  = 0.720, strain effect 
p  ̂  0.001). There was no difference between strains for 
right ventricular free wall thickness (data not shown). 
 In anaesthetised animals, ganglionic blockade had no 
significant effect on the Lewis blood pressures ( table 6 ) 
but it significantly reduced both systolic and diastolic ar-
terial pressures in the LPK, reducing systolic values to 
pressures comparable to the Lewis, and reducing diastol-
ic values to pressures less than the Lewis (in either the 
presence or absence of hexamethonium; p  ̂  0.05), indi-
cating a greater relative drop in diastolic pressures. These 
changes were reflected by the change in MAP (average 
fall of 4% in the Lewis and 53% in the LPK). There was 
no difference between pre- and post-hexamethonium 




























 Fig. 5. Cortical tubular epithelial cell (TEC) proliferation as eval-
uated by proliferating cell nuclear antigen (PCNA) staining.
 a Number of positive cells expressed as cells per mm 2 . There were 
significantly greater numbers of cells in the LPK relative to age-
matched Lewis controls at 3, 6 and 12 weeks of age.  *  Significant 
difference between LPK and Lewis at that age, p  ̂  0.05. There 
was no significant difference between the Lewis at any age, but the 
3- and 6-week-old LPK groups were significantly different to each 
other, and all other LPK age groups (adjusted R 2  = 0.854, strain 
effect p  ̂  0.001). Data are means  8 SD; n values are in table 5.
 b PCNA staining from a 3-week-old PKD. Original magnification 
 ! 200. 
 Table 5. Quantification of renal histopathological parameters in age-matched Lewis and LPK rats 
Parameter 1 week 3 weeks 6 weeks 12 weeks 24 weeks Adjusted 
R2 value(6)LEW (6)LPK (6)LEW (6)LPK (6)LEW (6)LPK (7)LEW (7)LPK (6)LEW (10)LPK
Vimentin, cora 0.380.2 1.480.5 0.180.1 3.080.4 0.280.2 3.380.8 0.280.2 3.980.1 0.280.2 4.080.1 0.97***
ED-1/mm2 b 9.380.9 14.085.6 5.181.1 14.082.6 6.081.4 34.1820.3 6.781.4 32.6822.7 8.886.8 20.9813.8 0.44***
Collagen, cxa 0.080.1 0.280.2 0.080 0.0380.1 0.180.1 0.2380.2 0.2680.2 1.380.4 0.480.2 2.580.5 0.93*
Collagen, meda 0.180.1 0.180.1 0.080.0 0.180.2 0.180.1 0.080 0.180.1 0.680.3 0.180.1 1.880.5 0.89***
-SMAc 5.081.2 3.681.1 1.180.3 3.682.4 1.280.6 9.782.9 1.180.6 10.083.5 0.880.3 12.282.3 0.82**
Data represent mean 8 SD of combined male and female data.
a Tubular vimentin staining and collagen deposition was scored with arbitrary units for the cortex (cx) or medulla (med).
b Immunoreactivity for ED-1 was measured as number of immunoreactive cells in midcortical fields per mm2.
c -Smooth muscle actin (-SMA) measured as  % of cortical area occupied by positive staining for -SMA.
Minimum number of animals in each group indicated by superscript associated with age/strain column. Significance of strain effect: * p ≤ 0.05;
** p ≤ 0.01; *** p ≤ 0.001.
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 Discussion 
 In this study we investigated the relationship between 
cyst formation and indicators of renal function and car-
diovascular disease in a new rat model of autosomal-re-
cessive PKD. Our data demonstrate that cyst formation 
preceded the development of hypertension, which in turn 
heralded significant increases in serum urea and creati-
nine, increased cardiac mass and LVH, and eventual end 
stage renal disease. A key finding was evidence for a sup-
pressed renin angiotensin system and heightened sympa-
thetic drive during the established phases of the disease. 
These finding therefore support the hypothesis that renal 
structural abnormalities are a key event in the genesis of 
hypertension and subsequent target organ disease in 
PKD. Given that the most important mechanism of limit-
ing renal disease progression is adequate blood pressure 





































































 Fig. 6. Hypertension and development of left ventricular hyper-
trophy.  a Systolic blood pressure (BP; mm Hg, as measured by tail 
cuff) and early and sustained presence of hypertension in the LPK 
animals as compared to Lewis control from week 6 (p  ̂  0.05, ad-
justed R 2  = 0.808, strain effect p  ̂  .001). There was no significant 
difference in blood pressure between the Lewis animals at any age 
nor between the 6-, 12-, 16- and 24-week-old LPK.  b  Heart weight 
data as a percentage of body weight (% BW) and significant dif-
ference between LPK and Lewis animals from 12 weeks of age
(p  ̂  0.05, adjusted R 2  = 0.86, strain effect p  ̂  0.001). There was 
no difference between Lewis animals at 6, 12, 16 and 24 weeks of 
age and there was no difference between the LPK animal at 6, 12, 
16 and 24 weeks of age.  c Transverse sections of rat hearts from a 
24-week-old Lewis (left) and a 24-week-old LPK (right), and dif-
ference in size of the hearts.  c  Scale bar = 2 mm.  d Thickness of 
left ventricular free wall (LVFW;   m) and the development of left 
ventricular hypertrophy in the LPK animals at 24 weeks of age
(p  ̂  0.05, adjusted R 2  = 0.836, strain effect p  ̂  0.05). Age has a 
significant effect on LVFW thickness in both strains (p  ̂  0.001). 
 *  Significant difference between LPK and Lewis at that age, p  ̂  
0.05. Data are means  8 SD, n values are as presented in  table 2 . 
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ship between cystogenesis and hypertension is key for 
providing effective therapeutic interventions. 
 The breeding analysis presented in this study con-
firms an autosomal recessive pattern of inheritance for 
PKD in the LPK model. Autosomal-recessive PKD has 
been shown to be due to mutations in the  PKHD1  gene 
 [22] , and indeed initial identification of the  PKHD1 gene 
arose from mapping of the  pck rat model, allowing iden-
tification of the human ortholog  [23] . The specific ge-
netic mutation and likely role of genetic modifiers, which 
are significant factors in human ARPKD  [24] , are not yet 
known for the LPK model and form the basis for current 
investigation by our group. Given that the functions and 
mechanisms of the genes currently known to cause PKD 
remain unclear, future identification of the responsible 
gene in this model will provide valuable insight into the 
pathogenesis of ARPKD in humans  [8, 23] . 
 The renal histopathology phenotype described in this 
study further supports our finding of an autosomal-re-
cessive mode of inheritance. Specifically, kidney enlarge-
ment was characterised by maintenance of the normal 
reniform shape, and cysts were due to fusiform dilatation 
predominantly of the collecting ducts and to a lesser ex-
tent other components of the distal nephron. Other auto-
somal-recessive forms of rodent PKD, such as the  wpk , 
also exhibit predominantly collecting duct-derived cysts 
 [10, 25] and in the spontaneously inherited  cpk mouse 
model of ARPKD, embryonic cystic lesions are localised 
to the proximal tubule  [26] . Likewise, in human ARPKD, 
renal disease is characterised in utero by fusiform dila-
tion of the collecting ducts  [22, 23] . This is in contrast to 
ADPKD, in both humans and murine models, where in 
general cysts are thought to arise from the tubular por-
tion of the nephron as well as the renal collecting system 
 [22] . 
 Our use of markers to identify cyst origin is substanti-
ated by studies in humans and other rodent models where 
aquaporins and THP have similarly been used to confirm 
nephron segment localization of cysts in PKD  [10, 19] . 
Indeed AQP1 and AQP2 belong to a group of proteins 
which retain their segment-specific discriminatory dif-
ferential expression even in end stage PKD  [27] . With re-
gard to the functional significance of staining for these 
proteins in cystic epithelia of the LPK model, it has been 
postulated that increased water permeability mediated by 
aquaporins could contribute to the pathogenesis of cyst 
formation by the facilitation of fluid secretion in to the 
cystic lumen  [27, 28] . Any potential role for THP, or uro-
modulin, however, is difficult to delineate, as the biolog-
ical role of this mucoprotein is still unclear  [28] . 
 Temporal analysis of the renal histopathology indicat-
ed three distinct structural-functional phases character-
ised by: (1) a precursor cystic phase (week 1); (2) a cystic 
phase (weeks 3–6) characterised by tubular epithelial cell 
proliferation and dedifferentiation, interstitial inflam-
mation with compensatory preservation of renal func-
tion, and (3) a cystic phase characterised by tubulointer-
stitial fibrosis correlating with progressive renal failure 
(12 weeks). At week 1 precursor cystic lesions (namely fo-
cal dilations of proximal and distal tubules) were present. 
By week 3, however, the medulla and cortex of the kidney 
were grossly deranged with the presence of diffuse cystic 
distal tubular dilatation only of predominantly collecting 
ductules. Interestingly, in the presence of this gross dis-
tortion in renal structure, the serum creatinine was nor-
mal but blood pressure was significantly elevated by week 
6. Cystic enlargement continued until week 24, but at a 
much slower rate and preceded the development of the 
other typical histological features of end-stage renal dis-
ease, including interstitial macrophage and myofibro-
Lewis LPK Adjusted 
R2 valuepre-Hex post-Hex pre-Hex post-Hex
Systolic AP, mm Hg 11188 10487 178819 84813* 0.88
Diastolic AP, mm Hg 6489 6587 8884 4182* 0.90
Mean AP, mm Hg 8088 7786 11888 5685* 0.92
Heart rate, bpm 270839 250829 326836 292828 0.37
Data represent mean 8 SD of combined data from animals of mixed sex aged 16 
weeks. Arterial pressures (AP) were measured from rats under urethane anaesthesia pre- 
and post-treatment with the ganglionic blocker hexamethonium (Hex, subcutaneous, 3.3 
mg/kg). Significant difference between pre- and post-treatment values: * p ≤ 0.05; n = 9.
 
 Table 6. Blood pressure and heart rate 
response to ganglionic blockade 
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blast accumulation, interstitial fibrosis and tubular cell 
dedifferentiation. 
 Renal function deterioration in progressive chronic 
kidney disease eventually leads to end stage renal failure 
and death. Systemic hypertension and proteinuria, char-
acteristics of the LPK model, are important progression 
factors underlying all forms of chronic kidney disease 
 [21] . In addition to the described change in serum cre-
atinine, laboratory abnormalities consistent with pro-
gression of renal dysfunction, including marked increas-
es in serum urea, isosthenuria, decreased serum protein, 
increased urinary protein to creatinine ratio and reduced 
PCV were also evident after week 12. The rate of progres-
sion of renal insufficiency in the LPK model resembles 
the time frame of morbidity for the ARPKD Wistar-chi 
and  pck (Crj:CD/SD) models  [10, 25, 29, 30] . However, 
unlike the Wistar-chi,  wpk or  pck ARPKD models, and 
also the heterozygous Han:SPRD ADPKD model, the 
LPK animals do not exhibit extra-renal pathology  [8, 31, 
32] . This is also in contrast to human ARPKD, which is 
characterised by the combination of renal cystic disease, 
congenital hepatic fibrosis, and the occasional occur-
rence of pancreatic fibrosis  [22] . 
 Of interest was the finding that LPK  animals demon-
strate gender dependent effects, with male animals show-
ing higher overall elevations in serum urea and creati-
nine. This is consistent with human PKD and other ani-
mal models, where males undergo more rapid disease 
progression and earlier onset of end stage renal disease 
 [33–35] . Studies in the Han:SPRD rat model suggest that 
oestrogen has a protective effect that promotes the pres-
ervation of renal function through the regulation of me-
diators of growth and fibrosis  [35] . 
 Hypertension is a common finding in both ADPKD 
and ARPKD in humans  [36, 37] and is an important fac-
tor that not only accelerates renal failure but also drives 
a spectrum of cardiovascular changes including LVH  [6, 
7, 38, 39] . In this study, blood pressure increased after 
early cystogenesis yet prior to marked increases in indica-
tors of renal function. In this regard, the LPK animals 
show a strong similarity to human PKD. In ADPKD, 60% 
of patients develop hypertension before renal function is 
impaired  [1] and in a recent retrospective study looking 
at ARPKD, hypertension was present in 55% of patients, 
with nearly all neonatal survivors requiring anti-hyper-
tensive treatment  [2] . As described, this is distinct to oth-
er rodent models of PKD which show no or only very mild 
to moderate elevations in blood pressure  [9–11, 35] . 
 Several mechanisms have been proposed regarding 
the pathogenesis of hypertension in PKD, including vol-
ume overload associated with an abnormal pressure-na-
turiesis response, activation of the RAAS associated with 
renal cyst formation and induction of local tissue isch-
aemia, and increased sympathetic activity  [40, 41] . With 
regard to the RAAS, there is conflict in the literature and 
it has been variably described as increased, decreased or 
unchanged  [3, 11, 40, 42, 43] . In ARPKD, it has been sug-
gested that affected neonates are actually in a low renin 
state  [2, 10] . In this study, both PRA and Ang II levels 
were low in LPK rats at 10–12 weeks of age. Markedly el-
evated systolic pressure and indicators of renal dysfunc-
tion at this age would suggest that extracellular fluid vol-
ume and total body sodium were likely to be increased 
 [44] . Given that sodium loading and increased arterial 
pressure reduce renin secretion  [45, 46] , this may explain 
the suppressed PRA. The reduced Ang II levels are likely 
to be linked to the low PRA, as a number of studies have 
shown that PRA and plasma Ang II are strongly corre-
lated  [47, 48] and respond similarly to interventions  [48, 
49] . However, suppressed renin at this time point does 
not exclude a role for renin in the early pathogenesis of 
hypertension. In one-kidney, one-clip Goldblatt hyper-
tension, renin is elevated in the early phase and contrib-
utes to the early rise in arterial pressure but once sodium 
retention occurs and arterial pressure rises the increase 
in renin subsides and renin is usually suppressed in the 
chronic phase  [50, 51] . Similar observations have been 
made in heart failure where, in animal models, renin ris-
es early and is suppressed in the chronic state, and hu-
mans where renin is raised in de-compensated heart fail-
ure and tends to fall in chronic stable disease  [52, 53] . 
 Aldosterone levels were variable in the LPK, and while 
on average not higher than control animals, did show a 
positive correlation with serum creatinine. The basis of 
this relationship is not known but a similar wide range of 
aldosterone levels in the presence of reduced PRA have 
been described previously in feline PKD  [54] . Given re-
newed interest in the role of aldosterone in renal disease 
progression  [55] , further studies to clarify the pathogen-
esis and therapeutic implications of this finding are war-
ranted. 
 In humans a number of studies have provided strong 
evidence for an important link between the observed 
sympathetic hyperactivity and increased risk of cardio-
vascular morbidity in PKD  [3, 4, 56] . Further, it has been 
shown that muscle sympathetic nerve activity is increased 
in hypertensive PKD patients regardless of renal function 
 [3] . In our study, sympathetic blockade was undertaken 
to gain further information about the role of the SNS in 
maintaining hypertension in PKD. The amount of hexa-
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methonium used was lower than used in other studies 
(1/10 th )  [57, 58] , and while it had no significant effect on 
the normotensive Lewis controls, it had a pronounced ef-
fect on the hypertensive LPK. With the caveat that estab-
lished hypertension induces vascular medial hypertrophy 
and a vascular amplifier effect  [59] , these results nonethe-
less suggest that maintenance of hypertension in the LPK 
rat is at least partly dependent on an intact SNS. 
 A number of mechanisms may drive sympathetic acti-
vation in PKD. It has been argued that renal ischaemia due 
to structural changes stimulates inappropriate activation 
of the renin-angiotensin system  [3, 56] , with high circu-
lating levels of Ang II in turn directly stimulating central 
sympathetic outflow via circumventricular organs that 
lack a functional blood brain barrier  [60, 61] . There is, 
however, an increasing field of study to suggest that intra-
renal ischaemia can modulate sympathetic efferent activ-
ity by direct stimulation of renal afferents  [3, 5] . For ex-
ample, in patients with end-stage renal failure, bilateral 
renal nephrectomy corrects increased muscle sympathet-
ic nerve activity concurrent with a reduction in blood 
pressure  [62] , and in animal models of renal failure/in-
jury, dorsal rhizotomy or renal denervation significantly 
attenuates the degree of hypertension  [63–65] . Given our 
finding of low levels of PRA and circulating Ang II, the 
LPK model will therefore be a useful tool for future evalu-
ation of these pathophysiological interactions between the 
renal, sympathetic and cardiovascular systems. 
 In conclusion, we have examined the temporal rela-
tionship between cardiac and renal disease progression 
in ARPKD, demonstrating that renal structural abnor-
malities precede the development of hypertension, in 
turn preceding marked changes in indices of renal dys-
function and cardiac hypertrophy. These data raise fur-
ther hypotheses, including the role of the RAAS and SNS 
in disease establishment and progression. It also raises 
questions as to whether diminution of renal cyst forma-
tion with anti-proliferative agents such as mammalian 
target of rapamycin inhibitors  [66] can reduce cardiovas-
cular morbidity by both slowing the development of hy-
pertension as well as direct inhibitory effects on cardiac 
structure. The key features of the LPK model including 
the course of disease progression indicate it is a suitable 
model in which to investigate the kidney-cardiovascular 
axis and genetic pathogenesis of PKD. 
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